Factors associated with variability in rifampin plasma pharmacokinetics and the relationship between rifampin concentrations and induction of efavirenz clearance

Pharmacotherapy

Volumn 34, Issue 3, 2014, Pages 265-271

  Kwara, Awewura ^a,b   Cao, Lei ^c   Yang, Hongmei ^d   Poethke, Pamela ^b   Kurpewski, Jaclynn ^b   Tashima, Karen T ^a,b   Mahjoub, Behrang D ^e   Court, Michael H ^c,f   Peloquin, Charles A ^e  

^a BROWN UNIVERSITY   (United States)

^b MIRIAM HOSPITAL   (United States)

^c TUFTS UNIVERSITY   (United States)

^d UNIVERSITY OF ROCHESTER   (United States)

^e UNIVERSITY OF FLORIDA HEALTH   (United States)

^f WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Drug interactions; Efavirenz; Pharmacogenetics; Pharmacokinetics; Rifampin

Indexed keywords

EFAVIRENZ; RIFAMPICIN; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1;

AFRICAN AMERICAN; AREA UNDER THE CURVE; ARTICLE; BODY MASS; BODY WEIGHT; CAUCASIAN; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISTRIBUTION VOLUME; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; GENE FREQUENCY; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MAXIMUM PLASMA CONCENTRATION; PHARMACOGENETICS; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM;

DRUG INTERACTIONS; EFAVIRENZ; PHARMACOGENETICS; PHARMACOKINETICS; RIFAMPIN;

ADULT; BENZOXAZINES; CROSS-OVER STUDIES; DRUG INTERACTIONS; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; ORGANIC ANION TRANSPORTERS; RIFAMPIN;

EID: 84898033401     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1388     Document Type: Article

References (34)

1. Blumberg HM, Burman WJ, Chaisson RE, et al. American thoracic society/centers for disease control and prevention/infectious diseases society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;4: 603-62.
2. Jindani A, Nunn AJ, Enarson DA. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet 2004;9441: 1244-51. (Pubitemid 39311345)
3. Okwera A, Whalen C, Byekwaso F, et al. Randomised trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans. The Makerere University-Case Western University Research Collaboration. Lancet 1994;8933: 1323-8. (Pubitemid 24343196)
4. Gumbo T, Louie A, Deziel MR, et al. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother 2007;11: 3781-8. (Pubitemid 350057771)
5. Jayaram R, Gaonkar S, Kaur P, et al. Pharmacokineticspharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2003;7: 2118-24. (Pubitemid 36753560)
6. Weiner M, Benator D, Burman W, et al. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis 2005;10: 1481-91. (Pubitemid 40628637)
7. Chang KC, Leung CC, Yew WW, Chan SL, Tam CM. Dosing schedules of 6-month regimens and relapse for pulmonary tuberculosis. Am J Respir Crit Care Med 2006;10: 1153-8. (Pubitemid 44772087)
8. Li J, Munsiff SS, Driver CR, Sackoff J. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000. Clin Infect Dis 2005;1: 83-91. (Pubitemid 40863749)
9. Giacomini KM, Huang SM, Tweedie DJ, et al. Membrane transporters in drug development. Nat Rev Drug Discov 2010;3: 215-36.
10. Chigutsa E, Visser ME, Swart EC, et al. The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications. Antimicrob Agents Chemother 2011;9: 4122-7.
11. Weiner M, Peloquin C, Burman W, et al. Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations. Antimicrob Agents Chemother 2010;10: 4192-200.
12. Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 2011;16: 1492-501.
13. Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011;16: 1471-81.
14. Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011;16: 1482-91.
15. Friedland G, Khoo S, Jack C, Lalloo U. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. J Antimicrob Chemother 2006;6: 1299-302. (Pubitemid 44884158)
16. Kwara A, Tashima KT, Dumond JB, et al. Modest but variable effect of rifampin on steady-state plasma pharmacokinetics of efavirenz in healthy African-American and Caucasian volunteers. Antimicrob Agents Chemother 2011;7: 3527-33.
17. Lopez-Cortes LF, Ruiz-Valderas R, Viciana P, et al. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet 2002;9: 681-90.
18. Schaid DJ, Batzler AJ, Jenkins GD, Hildebrandt MA. Exact tests of Hardy-Weinberg equilibrium and homogeneity of disequilibrium across strata. Am J Hum Genet 2006;6: 1071-80. (Pubitemid 44853478)
19. Breheny P, Huang J. Coordinate descent algorithms for nonconvex penalized regression, with applications to biological feature selection. Ann Appl Stat 2011;1: 232-53.
20. Fan J, Li R. Variable selection via nonconcave penalized likelihood and its oracle properties. J Am Stat Assoc 2001;456: 1348-60. (Pubitemid 33695585)
21. Jamis-Dow CA, Katki AG, Collins JM, Klecker RW. Rifampin and rifabutin and their metabolism by human liver esterases. Xenobiotica 1997;10: 1015-24. (Pubitemid 27450594)
22. Nakajima A, Fukami T, Kobayashi Y, Watanabe A, Nakajima M, Yokoi T. Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: rifampicin, rifabutin, and rifapentine. Biochem Pharmacol 2011;11: 1747-56.
23. Vavricka SR, Van Montfoort J, Ha HR, Meier PJ, Fattinger K. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 2002;1: 164-72. (Pubitemid 34700774)
24. Tirona RG, Leake BF, Wolkoff AW, Kim RB. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther 2003;1: 223-8. (Pubitemid 36008932)
25. Lubomirov R, di Iulio J, Fayet A, et al. ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. Pharmacogenet Genomics 2010;4: 217-30.
26. Kwara A, Lartey M, Sagoe KW, Court MH. Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy. AIDS 2011;3: 388-90.
27. Ngaimisi E, Mugusi S, Minzi O, et al. Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis. Clin Pharmacol Ther 2011;3: 406-13.
28. McIlleron HM, Schomaker M, Ren Y, et al. Effects of rifampin- based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype. AIDS 2013;12: 1933-40.
29. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT. Pharmacokinetic interactions with rifampicin : clinical relevance. Clin Pharmacokinet 2003;9: 819-50. (Pubitemid 36995083)
30. Faucette SR, Sueyoshi T, Smith CM, Negishi M, Lecluyse EL, Wang H. Differential regulation of hepatic CYP2B6 and CYP3A4 genes by constitutive androstane receptor but not pregnane X receptor. J Pharmacol Exp Ther 2006;3: 1200-9. (Pubitemid 43764125)
31. Faucette SR, Zhang TC, Moore R, et al. Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharmacol Exp Ther 2007;1: 72-80. (Pubitemid 46025721)
32. Mehta JB, Shantaveerapa H, Byrd RP Jr, Morton SE, Fountain F, Roy TM. Utility of rifampin blood levels in the treatment and follow-up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy. Chest 2001;5: 1520-4. (Pubitemid 33078467)
33. Mitchison DA. Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis 2000;9: 796-806.
34. Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002;15: 2169-83. (Pubitemid 35252827)